The Role of Endothelial Cell Injury in Thrombotic Microangiopathy

Bitzan, 2009, Treatment options for HUS secondary to Escherichia coli O157:H7, Kidney Int Suppl, 112, S62, 10.1038/ki.2008.624 George, 2009, The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: evaluation, management, and long-term outcomes experience of the Oklahoma TTP-HUS Registry, 1989-2007, Kidney Int Suppl, 112, S52, 10.1038/ki.2008.622 Noris, 2009, Atypical hemolytic-uremic syndrome, N Engl J Med, 361, 1676, 10.1056/NEJMra0902814 Sanchez-Corral, 2002, Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome, Am J Hum Genet, 71, 1285, 10.1086/344515 Noris, 2005, Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement, J Am Soc Nephrol, 16, 1177, 10.1681/ASN.2005010086 Eremina, 2008, VEGF inhibition and renal thrombotic microangiopathy, N Engl J Med, 358, 1129, 10.1056/NEJMoa0707330 Matsushita, 2003, Nitric oxide regulates exocytosis by S-nitrosylation of N-ethylmaleimide-sensitive factor, Cell, 115, 139, 10.1016/S0092-8674(03)00803-1 Nakayama, 2010, Endothelial von Willebrand factor release due to eNOS deficiency predisposes to thrombotic microangiopathy in mouse aging kidney, Am J Pathol, 176, 2198, 10.2353/ajpath.2010.090316 Germain, 2007, Endothelial dysfunction: a link among preeclampsia, recurrent pregnancy loss, and future cardiovascular events?, Hypertension, 49, 90, 10.1161/01.HYP.0000251522.18094.d4 Foster, 2009, The importance of cellular VEGF bioactivity in the development of glomerular disease, Nephron Exp Nephrol, 113, e8, 10.1159/000228078 Maynard, 2003, Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia, J Clin Invest, 111, 649, 10.1172/JCI17189 Venkatesha, 2006, Soluble endoglin contributes to the pathogenesis of preeclampsia, Nat Med, 12, 642, 10.1038/nm1429 Rother, 2005, The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease, JAMA, 293, 1653, 10.1001/jama.293.13.1653 Eremina, 2003, Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases, J Clin Invest, 111, 707, 10.1172/JCI17423 Delvaeye, 2009, Thrombomodulin mutations in atypical hemolytic-uremic syndrome, N Engl J Med, 361, 345, 10.1056/NEJMoa0810739 Dran, 2002, Protective role of nitric oxide in mice with Shiga toxin-induced hemolytic uremic syndrome, Kidney Int, 62, 1338, 10.1111/j.1523-1755.2002.kid554.x Kim, 2000, Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy, Kidney Int, 58, 2390, 10.1046/j.1523-1755.2000.00422.x Suga, 2001, Vascular endothelial growth factor (VEGF121) protects rats from renal infarction in thrombotic microangiopathy, Kidney Int, 60, 1297, 10.1046/j.1523-1755.2001.00935.x van den Born, 2008, Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension, Hypertension, 51, 862, 10.1161/HYPERTENSIONAHA.107.103127 Patterson, 2005, Interactive effects of superoxide anion and nitric oxide on blood pressure and renal hemodynamics in transgenic rats with inducible malignant hypertension, Am J Physiol Renal Physiol, 289, F754, 10.1152/ajprenal.00419.2004 Zhou, 2002, Nitric oxide synthase expression in hypertension induced by inhibition of glutathione synthase, J Pharmacol Exp Ther, 300, 762, 10.1124/jpet.300.3.762 Stirling, 1984, Haemostasis in normal pregnancy, Thromb Haemost, 52, 176, 10.1055/s-0038-1661167 Brenner, 2004, Haemostatic changes in pregnancy, Thromb Res, 114, 409, 10.1016/j.thromres.2004.08.004 George, 2003, The association of pregnancy with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, Curr Opin Hematol, 10, 339, 10.1097/00062752-200309000-00003 de Moerloose, 1998, Thrombomodulin levels during normal pregnancy, at delivery and in the postpartum: comparison with tissue-type plasminogen activator and plasminogen activator inhibitor-1, Thromb Haemost, 79, 554, 10.1055/s-0037-1614943 Fakhouri, 2010, Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations, J Am Soc Nephrol, 21, 859, 10.1681/ASN.2009070706 Kemmeren, 2004, Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor V Leiden mutation: a randomized trial, Blood, 103, 927, 10.1182/blood-2003-04-1285 Hauglustaine, 1981, Oestrogen containing oral contraceptives, decreased prostacyclin production, and haemolytic uraemic syndrome, Lancet, 1, 328, 10.1016/S0140-6736(81)91943-7 Hauglustaine, 1981, Recurrent hemolytic uremic syndrome during oral contraception, Clin Nephrol, 15, 148 Tolbert, 2001, Cardiovascular effects of estrogen, Am J Hypertens, 14, 186S, 10.1016/S0895-7061(01)02087-8 Bossi, 2008, Endothelial cells are a target of both complement and kinin system, Int Immunopharmacol, 8, 143, 10.1016/j.intimp.2007.08.006 Platt, 1991, The role of C5a and antibody in the release of heparan sulfate from endothelial cells, Eur J Immunol, 21, 2887, 10.1002/eji.1830211135 Ponticelli, 2006, Thrombotic microangiopathy after kidney transplantation, Transpl Int, 19, 789, 10.1111/j.1432-2277.2006.00354.x Brown, 1987, Cyclosporine inhibits prostacyclin production by cultured human endothelial cells, Transplant Proc, 19, 1178 Garcia-Maldonado, 1991, Decrease in endothelial cell-dependent protein C activation induced by thrombomodulin by treatment with cyclosporine, Transplantation, 51, 701, 10.1097/00007890-199103000-00030 Burke, 1999, Microangiopathy in kidney and simultaneous pancreas/kidney recipients treated with tacrolimus: evidence of endothelin and cytokine involvement, Transplantation, 68, 1336, 10.1097/00007890-199911150-00020 Burdmann, 2003, Cyclosporine nephrotoxicity, Semin Nephrol, 23, 465, 10.1016/S0270-9295(03)00090-1 Goldberg, 2009 Fortin, 2004, Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination, Am J Transplant, 4, 946, 10.1111/j.1600-6143.2004.00428.x Valavaara, 1985, Renal complications of mitomycin C therapy with special reference to the total dose, Cancer, 55, 47, 10.1002/1097-0142(19850101)55:1<47::AID-CNCR2820550108>3.0.CO;2-# Proia, 1984, Mitomycin-induced hemolytic uremic syndrome, Arch Pathol Lab Med, 108, 959 Maguire, 1993, Recurrent pancytopenia, coagulopathy, and renal failure associated with multiple quinine-dependent antibodies, Ann Intern Med, 119, 215, 10.7326/0003-4819-119-3-199308010-00006 Cantrell, 1985, Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy, J Clin Oncol, 3, 723, 10.1200/JCO.1985.3.5.723 Zheng, 2008, Pathogenesis of thrombotic microangiopathies, Annu Rev Pathol, 3, 249, 10.1146/annurev.pathmechdis.3.121806.154311 Orth, 2009, Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome, J Immunol, 182, 6394, 10.4049/jimmunol.0900151 Thurman, 2009, Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome, Clin J Am Soc Nephrol, 4, 1920, 10.2215/CJN.02730409 Karmali, 2009, Host and pathogen determinants of verocytotoxin-producing Escherichia coli-associated hemolytic uremic syndrome, Kidney Int Suppl, 112, S4, 10.1038/ki.2008.608 Fang, 2008, Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal stx-HUS, C3 glomerulonephritis, and the HELLP syndrome, Blood, 111, 624, 10.1182/blood-2007-04-084533 Banno, 2006, Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura, Blood, 107, 3161, 10.1182/blood-2005-07-2765 Motto, 2005, Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice, J Clin Invest, 115, 2752, 10.1172/JCI26007 John, 1998, Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study, Circulation, 98, 211, 10.1161/01.CIR.98.3.211 Blanco-Colio, 2003, Anti-inflammatory and immunomodulatory effects of statins, Kidney Int, 63, 12, 10.1046/j.1523-1755.2003.00744.x O'Driscoll, 1997, Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month, Circulation, 95, 1126, 10.1161/01.CIR.95.5.1126 Doehner, 2002, Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies, Circulation, 105, 2619, 10.1161/01.CIR.0000017502.58595.ED Mercuro, 2004, Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk, Am J Cardiol, 94, 932, 10.1016/j.amjcard.2004.06.032 Koh, 1999, Mechanism by which quinapril improves vascular function in coronary artery disease, Am J Cardiol, 83, 327, 10.1016/S0002-9149(98)00862-5 Koh, 2006, Anti-inflammatory and metabolic effects of candesartan in hypertensive patients, Int J Cardiol, 108, 96, 10.1016/j.ijcard.2005.07.040 Nagaya, 2004, Green tea reverses endothelial dysfunction in healthy smokers, Heart, 90, 1485, 10.1136/hrt.2003.026740 Vita, 2005, Polyphenols and cardiovascular disease: effects on endothelial and platelet function, Am J Clin Nutr, 81, 292S, 10.1093/ajcn/81.1.292S Beckman, 2001, Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans, Circulation, 103, 1618, 10.1161/01.CIR.103.12.1618 Yiginer, 2008, Allopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in metabolic syndrome, Clin Res Cardiol, 97, 334, 10.1007/s00392-007-0636-3 Butler, 2000, Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension, Hypertension, 35, 746, 10.1161/01.HYP.35.3.746 George, 2006, High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid, Circulation, 114, 2508, 10.1161/CIRCULATIONAHA.106.651117